Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study

NCT04793568 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT04793568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04793568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 29, 2021
Completion date
June 30, 2023
Enrollment
109 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

critically ill patients